NA Proactive news snapshot: CytoDyn, mCloud Technologies, NetCents Technology, Parallax Health Sciences …

CytoDyn Inc (OTCMKTS:CYDY) announced Monday that it has filed a modified investigational new drug (IND) application and protocol for the Phase 2 clinical trial of its versatile drug candidate leronlimab (PRO 140) as a therapy for patients who experience respiratory complications as a result of contracting the deadly coronavirus (COVID-19). In a statement, the Vancouver, Washington-based company said the “modification came at the behest of the US Food and Drug Administration,” in response to the company’s filing of its IND and protocol for its Phase 2 clinical trial on March 9. mCloud Technologies Corp (CVE:MCLD) (OTCMKTS:MCLDF) announced on Monday it is embedding advanced sensing technology from NYCE Sensors Inc, a provider of Internet of things solutions for commercial building applications, into its AssetCare solutions for Smart Facilities. mCloud said it has combined NYCE's wireless CO2 sensors for air duct management, building occupancy, and air quality measurement with the artificial intelligence and analytics provided by AssetCare.  NetCents Technology Inc (CSE:NC) (OTCMKTS:NTTCF), the cryptocurrency payments specialist, said it has further enhanced its software to allow for recurring billing, opening up a C$200 billion opportunity for the group. The firm said the move has enhanced its merchant gateway product for an entirely new customer base. Parallax Health Sciences Inc (OTCMKTS:PRLX) has received preliminary approval for registration on the US government's System for Award Management (SAM), a key step that will allow it to work with the Centers for Disease Control and Prevention (CDC) to develop a 15-minute coronavirus (COVID-19) detection test. The company is seeking a contract grant from the Atlanta-based agency’s Small Business Group to further develop its immunoassay diagnostics analyzer to detect coronavirus. TRACON Pharmaceuticals Inc (NASDAQ:TCON) announced Monday it has submitted a request for a Type B meeting with the US Food and Drug Administration to discuss the trial design for a potential pivotal ENVASARC study of envafolimab to treat sarcoma. In a statement, the company said it plans to propose a trial with two cohorts of about 80 patients each to assess the objective response rate in sarcoma subtypes known to be responsive to checkpoint inhibition -- with one cohort receiving single-agent envafolimab and the second cohort receiving envafolimab and Yervoy (ipilimumab). NexTech AR Solutions Corp (CSE:NTAR) (OTCMKTS:NEXCF) revealed Monday that it has signed a binding letter of intent to acquire remote video training, live streaming software company, Jolokia, which boasts customers like Merck and Toyota CBS. The Jolokia platform generated $1 million in Software as a Service (SaaS) revenue for 2019, the New York and Toronto-based augemented reality (AR) products company said in a statement. Azarga Metals Corp (CVE:AZR) has revealed it is getting a boost from London-listed Baker Steel Resources Trust Ltd (LON:BRST) in the form of an additional US$500,000 investment, the junior explorer announced Monday. The new funds come as part of an April 2019 agreement that saw Baker Steel invest US$3 million into Vancouver-based Azarga via an 8% secured convertible loan. Azarga said it plans to use the proceeds to advance drilling and exploration at its Unkur copper-silver project in Russia, which currently boasts an inferred resource of 62 million tons at 0.5% copper and 38.6 grams per ton silver. Global Energy Metals Corporation (CVE:GEMC) (OTCMKTS:GBLEF) is poised to bring in a gross sum of C$500,000 from a private placing to advance its battery metals development aims. The firm said it plans to carry out the financing after it has completed a 10:1 share split that it announced on March 10. The group will issue up to around 6.6 million units at a post-consolidation price of $0.075  each. Aurania Resources Ltd (CVE:ARU) (OTCMKTS:AUIAF) has said it is getting ready to advance work on the Ecuador-focused explorer's flagship Lost Cities-Cutucu project after closing a nearly C$6.5 million financing. The Toronto-based company closed the final tranche of a previously announced private placement comprised of C$837,000 to raise a total of C$6,470,131. Canntab Therapeutics Limited (CSE:PILL) (OTCMKTS:CTABF), a biopharmaceutical company focused on hard pill cannabinoid formulations, has closed the final $645,000 tranche of its previously-announced C$3.7 million private placement. The last tranche consisted of nearly 1.3 million units — each containing one share and one share purchase warrant — at a price of C$0.50 per unit. All told, the private placement consisted of 7.4 million units. "With the gross proceeds from this financing we now have the capital to completely implement our business plan,” Canntab CFO Richard Goldstein said in a statement. Permex Petroleum Corporation (CSE:OIL) (OTCMKTS:OILCF) has added experienced oil executive Greg Montgomery to its board of directors. The junior oiler said accountant and consultant Montgomery has held the office of chief financial officer for Oiltanking North America, Semarus Energy Advisors, Lion Copolymer, Coast Energy, and Laser Midstream. He was also a director of strategic planning for Enbridge Energy Partners and compliance officer for Pennzoil Company. Carube Copper Corp (CVE:CUC) (OTCMKTS:CARCF) said the plan to change its name to C3 Metals Inc was approved by over 96% of shareholder votes at an annual general and special meeting held in Toronto on February 28.  The meeting also saw the re-election of Tony Manini, Alar Soever, Zimi Meka, Stephen Hughes and Yale Simpson and the election of Kimberly Ann Arntson as directors. The appointment of PricewaterhouseCoopers LLP as the firm's auditors was also confirmed. Carube Copper also said the TSX Venture Exchange has consented to the extension in the expiry date of 24,029,750 warrants with original expiry dates of March 22, 2020, and March 29, 2020 to new expiry dates of March 22, 2021, and March 29, 2021, with an exercise price of 10 cents. It noted that these warrants were issued under a private placement of 50 million shares with 25 million share purchase warrants attached, which was accepted for filing by the exchange effective from April 4, 2018. OTC Markets Group Inc. (OTCQX:OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced JD Bancshares, Inc. (OTCQX:JDVB) has qualified to trade on the OTCQX Best Market and is upgraded to from OTC's Pink market. The OTCQX Market enables banks to maximize the value of being a public company by providing transparent trading and easy access to company information for shareholders. To qualify for OTCQX, community banks must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws. JD Bancshares, is the bank holding company of JD Bank, a state-chartered bank headquartered in Jennings, Louisiana. Bruce W. Elder, President and CEO said "The Company has served the southwest Louisiana market since 1947 and while we are well known in our local footprint, we look forward to telling our story and introducing JD Bank to a broader audience." Japan Gold Corp (CVE:JG) said the TSX Venture Exchange has accepted for filing the company's proposal to issue 500,000 bonus warrants exercisable at a price of 40 cents until March 9, 2021, to insider Southern Arc Minerals Inc. in consideration of a $1 million unsecured loan. Kincora Copper Ltd. (CVE:KCC) said late Friday that it will issue a total of 3,233,697 common shares for its third-quarter (July 1, 2019 to September 30, 2019) and for its fourth-quarter (October 1, 2019, to December 31, 2019) in consideration of services provided to the company The company noted that it will issue 1,358,697 common shares, at a deemed price of 6.9 cents per share as of September 30, 2019, and 1,875,000 common shares, at a deemed price of 0.5 cents per share as of December 31, 2019, to certain company directors, officers and service providers on account of services rendered during the two quarters. Dyadic International, Inc. (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, has announced that it will report its financial results for year ended December 31, 2019 after the market close on Monday, March 30, 2020 and it will host a conference call that day at 5:00pm Eastern Time to discuss those results. Conference Call Information:  Dial-in numbers: (877) 407-8033 (U.S. or Canada) or +(201) 689-8033 (International); Webcast Link: https://www.webcaster4.com/Webcast/Page/2031/33572.